SPL UNCLASSIFIED SECTION Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
3, 2023 from Novo Nordisk-c
Frequently Asked Questions Does DSIP actually induce sleep
Patients with a family history of medullary thyroid carcinoma should discuss risks thoroughly with their healthcare provider before starting therapy
While clinical validation of this mechanistic advantage continues to evolve, the dual-inhibition profile positions Polmacoxib as a promising therapeutic option for managing osteoarthritis
The use of this image is permitted to the author of the piece 3
